RxDoctor Payments Data

Norman Callahan, DO

Gastroenterology · Malvern, PANPI 1851367783

Payments from drug & device makers

$8,956in general payments, 2019–2025

Across 480 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$853
  • Takeda Pharmaceuticals U.S.A., Inc.$769
  • Pfizer$689
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$591
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$8,77199%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,956 in reported general payments places this provider in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$279,844
Medicare patients
713
Services billed
9,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab36$986,952
CreonLipase/Protease/Amylase11$45,175
LinzessLinaclotide15$17,479
Dexlansoprazole DrDexlansoprazole21$9,426
Pantoprazole Sodium223$3,351
Budesonide DrBudesonide19$2,892
Omeprazole267$2,882
Ursodiol15$2,549
Colestipol Hcl12$1,302
CholestyramineCholestyramine (With Sugar)20$606
Famotidine58$539
Dicyclomine Hcl17$421
Esomeprazole Magnesium14$233
Amitriptyline Hcl16$131
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,105$986,95236 claims
AbbVieCreon, Linzess$2,721$62,65426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Malvern

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →